FTLF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FTLF is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock is trading above its pivot with a modest daily gain, but the technical setup is mixed and there is no fresh catalyst, no strong proprietary buy signal, and analyst sentiment has turned more cautious after weak Q4 results. My direct view: hold off on buying for now.
FTLF closed at 11.55, slightly above the prior close of 11.5. The technical picture is neutral to mildly constructive but not decisive: RSI_6 is 59.6, which is neutral, MACD histogram is negative at -0.00754 though it is contracting, and moving averages are converging, suggesting a lack of clear trend strength. Price is near the pivot level of 11.454, with resistance at 12.415 and support at 10.493. This indicates the stock is still range-bound rather than in a strong uptrend.
The main positive factor is that some core products continue to show good growth, according to analyst commentary. The stock also finished the session in the green despite the broader market being slightly down, and similar candlestick pattern analysis suggests modest upside over the next week and month.
Roth Capital cut its price target to 17 from 25 after Q4 results missed expectations. The analyst cited slowing online product sales, higher protein costs, and the discontinuation of CBD as reasons for weaker earnings. There were no significant news items in the past week, hedge funds and insiders were neutral, and there is no recent congress or influential-person trading activity to support a bullish thesis.
Latest quarter: Q4. The available financial commentary points to earnings coming in below estimates, with declining performance in some online-sold products, margin pressure from high protein costs, and the removal of CBD contributing to weaker earnings trends. While a few core products still show growth, the overall latest-quarter picture appears mixed and somewhat weakening.
Recent analyst trend is negative-to-mixed: Roth Capital lowered the price target from 25 to 17 but kept a Buy rating after Q4 results disappointed. That means Wall Street still sees upside potential, but expectations have been reset lower. Pros: some core products are still growing and the rating remains Buy. Cons: slower online sales, margin pressure, discontinued CBD, and slowing momentum in parts of the product lineup.
